Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAG-3

LAG-3

Brief Information

Name:Lymphocyte activation gene 3 protein
Target Synonym:Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC,sLAG-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Approved

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
LAG-3 mAb Monospecific antibody Oncology/Cancer Advanced solid tumor Phase I Global

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
LA3-HP2H4 Human PE-Labeled Human LAG-3 / CD223 Protein, His TagStar Staining
LA3-HP2H4-structure
LA3-H52H3 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H52H3-structure
LA3-H52H3-sds
LA3-M82F3 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-M82F3-structure
LA3-M82F3-sds
LA3-M5253 Mouse Mouse LAG-3 / CD223 Protein, Fc Tag (MALS verified)
LA3-M5253-structure
LA3-M5253-sds
LA3-H82E9 Human Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-H82E9-structure
LA3-H82E9-sds
LA3-C8258 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling) (MALS verified)
LA3-C8258-structure
LA3-C8258-sds
LA3-C52H7 Canine Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-C52H7-structure
LA3-C52H7-sds
LA3-C82H3 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, His Tag
LA3-C82H3-structure
LA3-C82H3-sds
LA3-C82E5 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-C82E5-structure
LA3-C82E5-sds
LA3-M82E5 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-M82E5-structure
LA3-M82E5-sds
LA3-H82Fb Human Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-H82Fb-structure
LA3-H82Fb-sds
LA3-H525c Human Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H525c-structure
LA3-H525c-sds
LA3-H522a Human Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
LA3-H522a-structure
LA3-H522a-sds
LA3-H82F3 Human Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
LA3-H82F3-structure
LA3-H82F3-sds
LA3-H52Aa Human Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (MALS verified)
LA3-H52Aa-structure
LA3-H52Aa-sds
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (HPLC verified)
LA3-C52A0-structure
LA3-C52A0-sds
LA3-C52A0-hplc
LA3-C5252 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Fc Tag (MALS verified)
LA3-C5252-structure
LA3-C5252-sds
LA3-H5255 Human Human LAG3 / CD223 Protein, Fc Tag (MALS verified)
LA3-H5255-structure
LA3-H5255-sds
LA3-M52H5 Mouse Mouse LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-M52H5-structure
LA3-M52H5-sds
LA3-R52H5 Rat Rat LAG3 / CD223 Protein, His Tag (HPLC verified)
LA3-R52H5-structure
LA3-R52H5-sds
LA3-R52H5-hplc
LA3-H5222 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H5222-structure
LA3-H5222-sds
ACRO Quality

Customer Reviews

Synonym Name

LAG3,CD223,FDC

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Skin Melanoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Merkel Cell; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Relatlimab ONO-4482; BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Brain metastases; Uveal melanoma; Nasopharyngeal Carcinoma; Urinary Bladder Diseases; Sarcoma; Brain Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gliosarcoma; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Leukemia, Myeloid, Acute; Urogenital Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Large intestine neoplasm; Male Urogenital Diseases; Adenocarcinoma; Glioblastoma; Solid tumours; Female Urogenital Diseases and Pregnancy Complications; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Hodgkin Disease; Hematologic Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Medullary; Urologic Diseases; Female Urogenital Diseases; Urinary Bladder Neoplasms; Multiple Myeloma; Chordoma Details
Eftilagimod alpha IMP-321; hLAG-3Ig; CD-223; EDP-202; EOC-202 Phase 3 Clinical Immutep, Immutep Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Sarcoma; Breast Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Fianlimab REGN-3767 Phase 3 Clinical Regeneron Pharmaceuticals Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms Details
Mavezelimab/Pembrolizumab MK-4280A; MK-4820A Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Neoplasm Metastasis Details
SHR-1802 SHR-1802 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Tobemstomig RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LBL-007 LBL-007 Phase 2 Clinical Leads Biolabs Inc, Nanjing WeiLibo biological Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Negalstobart IBI-110 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Skin Melanoma; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
Mavezelimab MK-4280 Phase 2 Clinical Merck Sharp & Dohme Corp Lymphoma, B-Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Persistent Fetal Circulation Syndrome; Melanoma Details
Miptenalimab BI-754111 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
AK-129 AK-129 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Neoplasms; Adenocarcinoma Details
HLX-26 HLX-26 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
GLS-012 GLS-012 Phase 2 Clinical Harbin Gloria Pharmaceuticals Co Ltd Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
DNV-3 DNV-3; DNV3 Phase 2 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Neoplasms; Skin Neoplasms; Lymphoma; Melanoma Details
KL-A289 KL-A289 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Solid tumours Details
Bavunalimab XmAb-22841; XmAb-841 Phase 1 Clinical Xencor Inc Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Cholangiocarcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck Details
IMP-761 IMP-761 Phase 1 Clinical Autoimmune Diseases Details
Sym-022 Sym-022; Sym022; S95017 Phase 1 Clinical Symphogen A/S Solid tumours; Lymphoma; Neoplasm Metastasis Details
MIL-98 MIL-98 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Breast Neoplasms; Lymphoma; Melanoma Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Inc Solid tumours Details
AK-137 AK137; AK-137 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms Details
JY-03 JY03; JY-03 Phase 1 Clinical Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd Solid tumours Details
ZGGS-15 ZGGS15; ZGGS-15 Phase 1 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
TQB-2223 TQB2223; TQB-2223 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Neoplasms; Carcinoma, Hepatocellular Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Encelimab TSR-033; TSR 033; TSR033; GSK-4074386 Phase 1 Clinical Anaptysbio Inc Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message